



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
15 September 2020
8 July 2020

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Andrew Robert Donald Somervell
Fisher & Paykel Healthcare Corporation Limited
Not Applicable
Vice President - Products & Technology

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

(a) Cancellation of Options and issue of Ordinary Shares (b) Issue and Exercise of Performance Share Rights (c) Sale of Ordinary Shares
Beneficial

For that relevant interest

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) 128,823 Options (b) 42,631 PSRs (c) 71,044 Ordinary Shares
(a) 88,672 Options (b) 28,275 PSRs (c) 80,779 Ordinary Shares
Andrew Robert Donald Somervell
Andrew Robert Donald Somervell

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Not Applicable

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Two

Details of transactions requiring disclosure-

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):

(a) 4 & 14 September (b) 4 & 10 September (c) 11 & 14 September
(a) Issue of Options; cancellation of Options and issue of Ordinary Shares (b) Issue of PSRs; exercise of PSRs and issue of Ordinary Shares (c) Sale of Ordinary Shares

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest, -

Number held in class:

Current registered holder(s):

For a derivative relevant interest, -

Type of derivative:

Details of derivative, -

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest, -

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Cerification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

(a) \$nil

(b) \$nil

(c) \$1,721,271.31

(a) Issue of 20,090 Options; cancellation of 60,241 Options and issue of 41,007 Ordinary Shares;
(b) Issue of 6,372 PSRs; exercise of 20,728 PSRs and issue of 20,728 Ordinary Shares
(c) 52,000 Ordinary Shares



15 September 2020



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
15 September 2020
17 July 2020

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Paul Nigel Shearer
Fisher & Paykel Healthcare Corporation Limited
Senior Vice President - Sales & Marketing

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
For that relevant interest-
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

Ordinary Shares
Beneficial
(a) 180,853 Options (b) 78,983 PSRs (c) 356,661 Ordinary Shares
(a) 155,928 Options (b) 49,729 PSRs (c) 396,460 Ordinary Shares
Paul Nigel Shearer and Shearer Family Trust
Paul Nigel Shearer and Shearer Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

Not Applicable

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative,-

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

(a) 4 & 8 September (b) 4 & 9 September (c) 9 & 10 September
(a) Issue of Options; cancellation of Options and issue of Ordinary Shares (b) Issue of PSRs; exercise of PSRs and issue of Ordinary Shares (c) Sale of Ordinary Shares
(a) \$nil (b) \$nil (c) \$1,322,842.69

<p>Number of financial products to which the transaction related:</p> <p><i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i></p> <p>Whether relevant interests were acquired or disposed of during a closed period:</p> <p>Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:</p> <p>Date of the prior written clearance (if any):</p>

(a) Issue of 34,364 Options; cancellation of 59,289 Options and issue of 39,146 Ordinary Shares
 (b) Issue of 10,899 PSRs; exercise of 40,153 PSRs and issue of 40,153 Ordinary Shares
 (c) 39,500 Ordinary Shares

Summary of other relevant interests after acquisition or disposal:

<p>Class of quoted financial products:</p> <p>Nature of relevant interest:</p> <p><i>For that relevant interest,-</i></p> <p>Number held in class:</p> <p>Current registered holder(s):</p> <p><i>For a derivative relevant interest,-</i></p> <p>Type of derivative:</p>

Details of derivative,-

<p>The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):</p> <p>A statement as to whether the derivative is cash settled or physically settled:</p> <p>Maturity date of the derivative (if any):</p> <p>Expiry date of the derivative (if any):</p> <p>The price's specified terms (if any):</p> <p>Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:</p> <p><i>For that derivative relevant interest,-</i></p> <p>Parties to the derivative:</p> <p>If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:</p>


Cerification

<p>I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.</p> <p>Signature of director or officer:</p> <p>Date of signature:</p> <p>or</p> <p>Signature of person authorised to sign on behalf of director or officer:</p> <p>Date of signature:</p> <p>Name and title of authorised person:</p>

--

--

--


 15 September 2020
